financetom
Business
financetom
/
Business
/
Chipotle jumps on first ever stock-split as shares hover at record high
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chipotle jumps on first ever stock-split as shares hover at record high
Mar 20, 2024 5:52 AM

By Savyata Mishra

(Reuters) - Shares of Chipotle Mexican Grill ( CMG ) were up nearly 6% at $2960 premarket on Wednesday after the burrito chain's board approved a 50-for-1 stock split as the company looks to make the stock less expensive for potential investors.

Shares of the California-based company have rallied to record levels over the past year, powered by strong earnings owing to solid demand for burritos and rice bowls among its relatively wealthier customer base.

A stock split lowers the price of shares without affecting the company's valuation, making them more affordable for individual investors.

If the split is approved at the upcoming annual meeting on June 6, Chipotle's shareholders will receive an additional 49 shares for each share held.

The stock closed at $2,797.56 on Tuesday, making it the fourth-highest-per-share value on the S&P 500 index. Its market value was $76.71 billion.

The split, the first in its 30-year history, "will make our stock more accessible to employees as well as a broader range of investors," said Chipotle's Chief Financial and Administrative Officer Jack Hartung on Tuesday.

Based on Tuesday's closing price, the stock would trade at around $56/share after the split. The company has around 27.4 million shares outstanding.

"Chipotle's stock split should ease liquidity in the stock given how high the share price has risen over the past years. Otherwise, the economics of the business remain just as compelling," said Jim Sanderson, an analyst with Northcoast Research.

Its forward price-to-earnings multiple (P/E), a common benchmark for valuing stocks, is 49.72, higher than industry peers including Starbucks and McDonald's that have a P/E ratio of 20.89 and 22.24 respectively.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blue Bird CEO Phil Horlock to Take Additional Role as President
Blue Bird CEO Phil Horlock to Take Additional Role as President
Sep 9, 2024
09:59 AM EDT, 09/09/2024 (MT Newswires) -- Blue Bird ( BLBD ) said Monday that Chief Executive Phil Horlock will take on an additional role as the company's president following Britton Smith's resignation from the position, effective Sept. 28. Smith has resigned as president due to personal reasons, the company said. Price: 46.62, Change: +0.30, Percent Change: +0.65 ...
Wendy's Names Arthur Winkleblack Non-Executive Chairman
Wendy's Names Arthur Winkleblack Non-Executive Chairman
Sep 9, 2024
10:00 AM EDT, 09/09/2024 (MT Newswires) -- Wendy's (WEN) said Friday that its board has named Arthur Winkleblack as non-executive chairman of the board. Winkleblack, who was also appointed as chairman of the executive committee, succeeds Nelson Peltz, who was named chairman emeritus, according to the company. Winkleblack had been the lead independent director at Wendy's since October 2023 and...
Lucid Group Rolls Out New Features for Air Electric Vehicle in Latest Software Update
Lucid Group Rolls Out New Features for Air Electric Vehicle in Latest Software Update
Sep 9, 2024
10:02 AM EDT, 09/09/2024 (MT Newswires) -- Lucid Group ( LCID ) said Monday it has launched an over-the-air software update for the Lucid Air electric vehicle to support the DreamDrive Pro driver assistance system and add a voice control feature, Lucid Assistant. The company said the update is available in North America starting today. The Lucid UX 2.4 software...
Cartesian Therapeutics' Descartes-08 Secures FDA Rare Pediatric Disease Designation to Treat Juvenile Dermatomyositis
Cartesian Therapeutics' Descartes-08 Secures FDA Rare Pediatric Disease Designation to Treat Juvenile Dermatomyositis
Sep 9, 2024
09:54 AM EDT, 09/09/2024 (MT Newswires) -- Cartesian Therapeutics ( RNAC ) said Monday its Descartes-08 cell therapy candidate received rare pediatric disease designation from the US Food and Drug Administration for the treatment of juvenile dermatomyositis. The cell therapy candidate is designed to be administered without preconditioning chemotherapy and doesn't use integrating vectors, the company said. The regulator grants...
Copyright 2023-2026 - www.financetom.com All Rights Reserved